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Introduction
Bromocriptine Mesylate (BC) is an ergot derivative with
potent dopamine receptor agonist activity. It is licensed to
reduce plasma levels of prolactin. BC has central nervous
effects, and is used in patients with Parkinson’s disease.
There are few randomized controlled trials with BC con-
ducted in moderate brain injury (BI) with conflicting
results (1). We aim to present our single center experience
on dopaminergic challenge using off-label BC in patients
with severe BI.
Methods
Glasgow Coma Score (GCS) are 3-10 (GCS: worst score
= 3, best score = 15) at beginning of BC administration.
Patients received 2.5mg of BC q6h after hemodynamic
stability was ensured and no further neurologic
improvement was observed during course of manage-
ment. BC was started and discontinued on the discre-
tion of the ICU team. Long term cognitive tests are
under assessment.
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Table 1 GCS of patients on admission, beginning treatment, end of treatment and discharge. GCS of patients on
admission, beginning treatment.
Patient Number GCS admission GCS start GCS end BC started on day Days on BC Days in ICU GCS discharge
1 3 4 8 29 9 38 8
2 5 5 5 16 8 39 5
3 15 10 14 25 4 29 14
4 3 3 6 11 30 64 12
5 3 3 5 6 23 39 5
6 3 6 10 28 8 70 died
7 3 3 4 9 7 75 6
8 3 4 4 24 15 40 died
9 4 4 5 9 34 49 8
10 4 4 7 10 35 46 died
11 3 8 3 9 7 18 died
12 3 4 4 11 7 18 8
13 3 6 6 11 19 30 6
14 6 6 8 1 21 37 10
15 5 5 5 9 4 51 8
16 5 6 7 11 30 47 7
17 3 6 5 28 25 64 died
18 3 4 5 32 17 59 5
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Results
A total of 18 patients were treated with BC. The average
age was 48.9 (82-18) (12M/6F).
Conclusions
Our results show some neurologic improvement as
assessed by GCS. More research is warranted before BC
can be recommended in BI.
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